PVT In Patients With Chronic Liver Disease Dominique-Charles Valla Hôpital Beaujon, APHP, Université Paris-7, Inserm CR3B Cooperation Bilharz-Beaujon Cairo.

Slides:



Advertisements
Similar presentations
Alfredo ALBERTI. How to predict outcome in hepatitis C patients Alfredo Alberti Department of Clinical and Experimental Medicine Venetian Institute of.
Advertisements

AM Report Lauren Galpin, MD MA  “Thromboembolic obstruction of the major pulmonary arteries due to unresolved pulmonary embolism [with pulmonary.
Teaching Liver cirrhosis with varices. Discussion  Approximately half of patients with cirrhosis have esophageal varices  One-third of all patients.
PORTAL VEIN THROMBOSIS; ANTICOAGULANT ?YES AND NO Dr. MOHAMMED EMAM Prof. tropical medicine and Hepatology ZAGAZIG UNIVERSITY 2011.
1 THROMBOPHILIA. 2 Thrombophilia is technical term for hypercoagulable state Thrombosis (arterial or venous) is produced by a shift in the balance between.
Joint Hospital Surgical Grand Round
Thrombophilia. Now considered a multicausal disease, with an interplay of acquired and genetic thrombotic risk factors Approximately half of venous thromboembolic.
Pathology 430/826 Thrombosis David Lillicrap. Cardiovascular Disease 30% of all deaths in Canada 54% ischemic heart disease 20% stroke 23% heart attack.
Bleeding time,clotting time, PT, and PTT
Dr msaiem Acquired Coagulation Disorders Dr Mohammed Saiem Al-dahr KAAU Faculty of Applied Medical Sciences.
Protein C and Protein S Deficiency Paolo Aquino 18 February 2003.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
Complications of Liver Cirrhosis Ayman Abdo MD, AmBIM, FRCPC.
Venous thromboembolism: how long to treat?
Liver pathology: CIRRHOSIS
Thrombophilia For the Clinician
Thrombophilias Sharon Sams. Objectives Overview of etiology of hypercoagulability Available tests Clinical correlation or “What do I do with these results?”
Dr Nico Lategan MBChB, MMed (Haematology)
PORTAL HYPERTENSION & CHRONIC LIVER DISEASE SEAN CHEN ST GEORGE HEPATOBILIARY & PANCREATIC WORKSHOP 31/05/2014.
MANAGEMENT CONFERENCE A middle age woman with abdominal pain and ascitis.
Haematological and vascular complications affecting the liver Dominique-Charles Valla Hôpital Beaujon, Clichy, France BSG Postgraduate Course Birmingham.
International Congress Highlights 2004 Clinical Update in GI disease Portal Hypertension P. Michielsen University of Antwerp
APPROACH TO BLEEDING DISORDERS. History of Bleeding Spontaneous vs. trauma/surgery-induced Ecchymoses without known trauma Medications or nutritional.
Portal Hypertension portal venous pressure > 5 mmHg
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
Renal vein thrombosis Nephrology discussion Dr. Coetser Prof. Van Rensburg and dr. Rossouw.
Principles of anesthesia in cirrhotic patients
THROMBOTIC COMPLICATIONS OF PANREATIC CANCER: A CLASSICAL KNOWLEDGE REVISITED D. L. DUMITRASCU, O. SUCIU, C. GRAD, D. GHEBAN 2 ND MEDICAL DEPT. UMPh IULIU.
Hypercoagulable Syndromes. Risk Factors For Venous Thrombosis ACQUIREDINHERITEDMIXED/UNKNOWN Advancing ageAntithrombin Deficiency  Homocysteine ObesityProtein.
Anticoagulación en la Cirrosis e HTP no cirrótica Juan Carlos Garcia-Pagán Barcelona Hepatic Hemodynamic Laboratory. Liver Unit. IMDIM. Hospital Clinic.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Thrombophilia National Haemophilia Director
PORTAL VEIN THROMBOSIS
Hypercoagulable States. Acquired versus inherited Acquired versus inherited “Provoked” vs idiopathic VTE “Provoked” vs idiopathic VTE Who should be tested.
Thrombophilia (Hypercoagulable States) Abdulkareem Almomen, MD Professor of Medicine & Hematology, King Saud University MED 341, Feb.2014.
Thrombophilia. Definition –Tendency to develop clots due to predisposing factors that may be genetically determined.
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
HCC Guidelines
Complications of liver cirrhosis
Venous thromboembolic disease
Inherited bleeding disorder of primary hemostasis.
Hematology Blueprint PANCE Blueprint. Coagulation Disorders.
Complications of liver cirrhosis
LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES. REGULATION OF COAGULATION Introduction Coagulation necessary for maintenance of vascular integrity Enough.
Complications of Liver Cirrhosis
Deep vein thrombosis and pulmonary embolism.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Exam review GIT and Liver, Gall bladder. Liver Hepatitis Circulatory diseases.
DIC. acute, subacute or chronic widespread intravascular fibrin formation in response to excessive blood protease activity that overcomes the natural.
Management of patients with cirrhosis and refractory ascites Treviso 4 Giugno 2009 P. Angeli Dept. of Clinical and Experimental Medicine University of.
Haemostasis. Indications for hemostasis test – Identify patients presenting with bleeding that have a correctable bleeding tendency – Identify patients.
Portal Vein Thrombosis in Children and Adolescents
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Course Lecturer: Imon Rahman
LIVER HEALTH an integral part of CF gastrointestinal care Zachary M Sellers, MD, PhD Fellow Pediatric Gastroenterology, Hepatology, and Nutrition Stanford.
Obada Al-Eisa Saud Bashtawy Emad Mansour.  It is an acquired condition characterized by massive activation of the coagulation system.  It is always.
Dr. Mohammed Omar Khalifa
Venous Thromboembolism Prophylaxis for Medical Inpatients
Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H
Thrombosis.
Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H
By: Dr. Nalaka Gunawansa
Ultrasound Evaluation of Visceral Veins
Discounted Coagulation Profiles Clinical Laboratories.
Coagulopathy in acute and chronic liver diseases - Transfusion choices based on Coagulation screen for procedures Ashish Goel Department of Hepatology.
Thrombophilia.
Management of non neoplastic portal vein thrombosis in the setting of liver transplantation (LT) Journal club 18/02/2019 Specializzanda: Dott.ssa C. Chialà.
DR. TANVEER HUSSAIN FCPS(Medicine) FCPS (Gastroenterology)
Nephrotic syndrome is a prothrombotic state of variable magnitude.
Susana G. Rodrigues, MD-PhD student; Apr ‘17-Jul ’19, funded by the Stiftung für Leberkrankheiten Bern 1. Portal vein recanalisation with transjugular.
Presentation transcript:

PVT In Patients With Chronic Liver Disease Dominique-Charles Valla Hôpital Beaujon, APHP, Université Paris-7, Inserm CR3B Cooperation Bilharz-Beaujon Cairo - March 16-18, 2008

PVT in Patients with Cirrhosis Epidemiology Manifestations Causal factors Therapy

Prevalence of Overt PVT in Cirrhosis Screening for HCC 0.6 % In-Hospital 7.0 % Necropsy 8.0 % Before LTx or PSS 15.0 % Okuda et al. Gastroenterology 1985;89: Chang et al. J Pathol Bacteriol 1965;89:

Incidence of PVT in Patients with Cirrhosis Amitrano, Endoscopy Francoz et al. Gut % pt/yr Listed for liver transplantation Sclerotherapy 12% pt/yr

Prevalence of Occult PVT in Cirrhosis Liver explants Wanless et al. Hepatology 1995;21: Small mural thrombus 64 % Large veins (intimal fibrosis) 25 % Small veins (intimal fibrosis) 36 % % Veins involved

Prevalence of Overt PVT in Schistosomiasis Preoperative 5 % Splenectomy/Devascularization 19 % Distal splenorenal shunt50 % Widman. Hepatogastroenterology 2003

PVT in Patients with Cirrhosis Epidemiology Manifestations Causal factors Therapy

PVT and Cirrhosis: Associations Portal hypertensive bleeding Failure to control bleeding Ascites Hepatic encephalopathy Hyperdynamic circulation Intestinal ischemia or infarction Nonami Hepatology Orloff J Gastrointest Surg D’Amico Hepatology Amitrano J Hepatol 2004.

PVT and Cirrhosis: Associations Nonami et al. Hepatology 1992;16: At LTxNLiver weight PVT 6317 g/Kg No PVT40121 g/Kg P <.02

Thrombosis Advanced Liver Disease Decreased Portal Blood Inflow Blood stasis Wall changes (PHT) Thrombosis Advanced Liver Disease

PVT in Patients with Cirrhosis Epidemiology Manifestations Causal factors Therapy

THROMBOSIS External Factors Environmental Local factors Internal Factors Prothrombotic Disorders Causes For Venous Thrombosis Acquired Inherited

Inherited Prothrombotic Disorders Loss of function Inhibitors (PC, PS, AT) Uncommon (< 0.1%) High risk Dg: Plasma level Gain of function Factors (FV, FII) Common (> 2.0%) Moderate risk Dg: DNA analysis

Acquired Prothrombotic Disorders Common Moderate risk Inflammatory states Malignancy Hyperhomocysteinemia … Uncommon High risk Myeloproliferative dis. APL syndrome PNH Behcet’s disease …

Inherited Prothrombotic Disorders Loss of function Inhibitors (PC, PS, AT) Uncommon (< 0.1%) High risk Dg: Plasma level Gain of function Factors (FV, FII) Common (> 2.0%) Moderate risk Dg: DNA analysis

Coagulation Inhibitors in Cirrhosis Romero-Gomez. J Clin Gastroenterol % Protein C Protein S Antithrombin A B C 50% 0% 75% Child-Pugh BC A BC A BC A

Acquired Prothrombotic Disorders Common Moderate risk Inflammatory states Malignancy Hyperhomocysteinemia … Uncommon High risk Myeloproliferative dis. APL syndrome PNH Behcet’s disease …

PVT and Cirrhosis: Antiphospholipid Ab Mangia, Am J Gastroenterol Dalekos, Eur J Gastro Hepato Munoz-Rodriguez, J Hepatol Prieto, Hepatology Quintarelli, J Hepatol Violi, Hepatology Romero-Gomez J Clin gastro 2000 ACL common in chronic liver diseases (20%) Usually non specific (low fluctuating titer, no LA)

Risk Factors for Portal Vein Thrombosis. Cirrhosis without HCC Univariate:Age, Child-Pugh class, Surgery for portal hypertension Endoscopic sclerotherapy Prothrombotic features Mangia, Am J Gastroenterol Nonami, Hepatology Davidson, Transplantation *Amitrano, J Hepatol 2004.

PVT and Cirrhosis: Prothrombotic Disorders With PVTNo PVT p Amitrano et al. Hepatology 2000;31: F. V Leiden F. II gene mutation C677T MTHFR At least one Two or more 13 % 35 % 43 % 70 % 22 % NS <.05 <.01 7 % 2 % 5 % 14 % 0

Risk Factors for Portal Vein Thrombosis. Cirrhosis without HCC Univariate:Age, Child-Pugh class, Surgery for portal hypertension Endoscopic sclerotherapy Prothrombotic features Mangia, Am J Gastroenterol Nonami, Hepatology Davidson, Transplantation *Amitrano, J Hepatol Multivariate:G20210A FII (OR 5.94*)

PVT in Patients with Cirrhosis Epidemiology Manifestations Causal factors Therapy

PVT and Cirrhosis: Why to treat? To prevent aggravation ? To facilitate transplantation

Portal Vein Thrombosis Clinical results of anticoagulant therapy In patients without cirrhosis In patients with cirrhosis

Acute PVT: Complete Recanalization Pts at risk: Time to recanalization (months) Recanalization (%)

Chronic Portal Vein Thrombosis Condat et al. Gastroenterology 2001; 120:490 Thrombosis 6.0 yes no yes no Anticoagulation 1.2 Bleeding 7 17 per 100 patients per year p = p = 0.212

Orr et al. Hepatology 2005; 42: 212A (AASLD San Francisco 2005) Chronic portomesenteric venous thrombosis HR for Death yes no Warfarine p=0.038

Patients on the Waiting List for LTx PVT before transplantation (n = 29) Anticoagulation (n = 19) Recanalization (n = 8) Francoz, Gut 2005 No anticoagulation (n = 10) Recanalization (n = 0)

TIPS for PVT in Cirrhosis Limited data Feasible and safe Risk of obstruction unclear Risk of encephalopathy unclear Benefit unclear Senzolo Alim Pharmacol Therap Van Ha Cardiovasc Intervent Radiol Bauer Liver Transplant 2006

PVT and Cirrhosis: Summary Common in end-stage cirrhosis Uncommon in well-compensated cirrhosis Causal factors: surgery, stasis, thrombophilias A marker for severity: certainly A cause for aggravation: uncertain A limitation for liver transplantation: certainly

PVT and Cirrhosis: What we do in Beaujon Objectives:Recanalization (recent thrombus) Prevention of thrombus extension Indications:→ Child A with thrombophilia → Patients listed for LTx Monitoring:Anti-Xa 0.5 U/ml Factor II 25% to 35%

Hemostasis in Cirrhosis Normal thrombin generation in platelet-poor plasma. Decreased thrombin generation in severely thrombocytopenic blood. Elevated levels of vWF support platelet adhesion despite reduced functional capacities. Caldwell. Hepatology 2006

INR in Patients with Cirrhosis Not related to prothrombin levels along the same regression line as for Vitamin K antagonists. Due to uncarboxylated metabolites of coagulation factors Interlaboratory variability. → Adjustment based on Factor II level 25-35%?

Patients on the Waiting List for LTx PVT before transplantation 24 Complete 3 Recanalization 0 Francoz, ILTS 2008 Partial 21 Recanalization* 15 * No post-OLT PVT

Recanalisation 83 % Anticoagulation (alone, n = 27) Condat. Hepatology 2000 Thrombolysis (in situ, n = 20) 75 % Acute Portal Vein Thrombosis Holliingshead. J Vasc Interv Radiol 2005

Acute Portal Vein Thrombosis Major Bleeding 60% Thrombolysis (in situ, n = 20) 5% Anticoagulation (alone, n = 27) Condat. Hepatology 2000 Holliingshead. J Vasc Interv Radiol 2005 %